Thyrocare Technologies Reports Strong Growth in Q4 and FY25, Achieves 100% NABL Accreditation

1 min read     Updated on 23 Apr 2025, 05:32 PM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Thyrocare Technologies Limited announced robust financial results for Q4 and FY25. Q4 saw a 21% YoY revenue increase to INR 187.20 crore, with 78% EBITDA growth and 88% PAT surge. FY25 annual revenue rose 20% to INR 687.30 crore, with 37% EBITDA growth and 45% PAT increase. The company became India's first 100% NABL accredited national diagnostic lab chain, processed 167.9 million tests, and expanded its franchisee network. Strategic acquisitions of Polo Labs and Vimta Labs' diagnostic business were completed. The Board recommended a final dividend of INR 21.00 per share.

6955360

*this image is generated using AI for illustrative purposes only.

Thyrocare Technologies Limited , a leading diagnostic services provider, has announced its financial results for the fourth quarter and fiscal year ended March 31, 2025, showcasing robust growth and operational achievements.

Q4 FY25 Highlights

  • Consolidated revenue increased by 21% year-over-year to INR 187.20 crore
  • Normalized EBITDA grew by 78% to INR 65.30 crore
  • Profit after tax (excluding exceptional items) surged by 88% to INR 32.50 crore

FY25 Performance

  • Annual consolidated revenue rose by 20% to INR 687.30 crore
  • Normalized EBITDA for the year increased by 37% to INR 209.90 crore
  • Profit after tax (excluding exceptional items) grew by 45% to INR 101.20 crore

Operational Achievements

Thyrocare reached a significant milestone by becoming India's first and only 100% NABL accredited national diagnostic laboratory chain. This accreditation covers 29 Thyrocare-owned labs across India, excluding recently acquired facilities and partner labs.

The company processed a total testing volume of 167.9 million in FY25, which it claims is the largest in terms of volume. The number of active franchisees grew by 16% to over 11,000, while the patient count increased by 11% to 16.7 million.

Strategic Expansions

During FY25, Thyrocare completed two strategic acquisitions:

  1. Polo Labs Private Limited: This acquisition strengthened Thyrocare's presence in Punjab, Haryana, and Himachal Pradesh.
  2. Clinical diagnostic business of Vimta Labs: This move expanded Thyrocare's footprint in southern India.

Additionally, the company extended its ECG at Home services to 1,150 pincodes by Q4FY25, up from 650 pincodes in Q1FY25.

Financial Position

Thyrocare's consolidated cash reserves stood at INR 191.80 crore as of March 2025. The Board of Directors has recommended a final dividend of INR 21.00 per equity share for FY25, subject to shareholder approval.

Management Commentary

Rahul Guha, Managing Director of Thyrocare Technologies Limited, stated, "Our strong performance in Q4 and throughout FY25 reflects our commitment to quality and operational excellence. The achievement of 100% NABL accreditation for our labs underscores our dedication to maintaining the highest standards in diagnostic services."

Future Outlook

With its expanded network, strategic acquisitions, and focus on quality, Thyrocare is well-positioned to capitalize on the growing demand for diagnostic services in India. The company continues to invest in technology and infrastructure to enhance its service offerings and maintain its competitive edge in the market.

Note: All financial figures are in Indian Rupees (INR).

Historical Stock Returns for Thyrocare Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
+0.28%+9.01%+14.19%+41.00%+81.81%+104.46%
Thyrocare Technologies
View in Depthredirect
like18
dislike

Thyrocare Technologies Strengthens Tanzanian Joint Venture with $25,000 Investment

2 min read     Updated on 03 Mar 2025, 08:06 PM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Thyrocare Technologies has invested an additional $25,000 (₹21.98 lakh) in its Tanzanian joint venture, Thyrocare Laboratories (Tanzania) Limited. This investment is part of a larger ₹15 crore plan. The joint venture, operational since April 2024, reported a turnover of ₹0.44 crore for the nine months ended December 31, 2024. With this investment, Thyrocare's stake temporarily exceeds 50%, potentially making the joint venture a subsidiary. The shareholding is expected to revert to 50:50 once partners contribute their equity portion.

2558207

*this image is generated using AI for illustrative purposes only.

Thyrocare Technologies Limited , a prominent player in India's diagnostic services sector, has reinforced its commitment to international expansion by making an additional investment in its Tanzanian joint venture. The company disclosed this strategic move in a recent filing to the stock exchanges.

Investment Details

Thyrocare Technologies has injected an additional $25,000 (equivalent to approximately ₹21.98 lakh) into Thyrocare Laboratories (Tanzania) Limited, its joint venture company. This investment, made on March 3, 2025, is part of a larger approved investment plan of up to ₹15 crore, to be executed in multiple tranches based on business requirements.

Joint Venture Overview

Thyrocare Laboratories (Tanzania) Limited, incorporated on September 19, 2023, operates in the diagnostic and healthcare services sector in Tanzania. The joint venture commenced operations in April 2024 and has shown promising initial results:

Metric Value Period
Turnover ₹0.44 crore Nine months ended December 31, 2024
Net worth ₹3.21 crore As of December 31, 2024

Shareholding Structure

While the original agreement stipulated a 50:50 shareholding between Thyrocare Technologies and its joint venture partner, the recent investments have temporarily altered this balance. With the current $25,000 investment and a previous $100,000 injection on December 3, 2024, Thyrocare Technologies has now contributed more than 50% of the total investment in the joint venture.

Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies, stated in the filing:

"Upon the allotment of shares by the JV Company, the JV Company will become a subsidiary of the Company."

However, this situation is expected to revert to the agreed 50:50 structure once the other joint venture partners contribute their portion of the equity.

Strategic Implications

This additional investment underscores Thyrocare Technologies' commitment to expanding its footprint in the East African market. The company aims to leverage its expertise in providing diagnostic and healthcare services to tap into the growing healthcare sector in Tanzania.

Regulatory Compliance

The transaction has been carried out at arm's length and falls under the category of a related party transaction. Thyrocare Technologies has assured that necessary filings and reporting will be made as per applicable laws.

Conclusion

As Thyrocare Technologies continues to strengthen its international presence, this strategic investment in Tanzania represents a significant step in the company's global expansion strategy. Investors and industry observers will be keenly watching how this joint venture performs and contributes to Thyrocare's overall growth in the coming years.

Historical Stock Returns for Thyrocare Technologies

1 Day5 Days1 Month6 Months1 Year5 Years
+0.28%+9.01%+14.19%+41.00%+81.81%+104.46%
Thyrocare Technologies
View in Depthredirect
like20
dislike
Explore Other Articles
Indonesia Inks $19.5 Billion Trade Deal with U.S., Including Major Boeing Purchase 31 minutes ago
Arisinfra Solutions Signs ₹75 Crore Supply Agreement with Wadhwa Construction 5 hours ago
3I Infotech's US Subsidiary Secures $2.14 Million Employee Retention Credit 2 hours ago
Rajoo Engineers Launches QIP with Floor Price of ₹114.42 Per Share 4 hours ago
1,164.70
+3.25
(+0.28%)